Mass Tort brief
Trial Bellwethers and Multibillion-Dollar Thresholds Put Device Makers and Pharma on Notice
Federal dockets test corporate liability from catheter sepsis to infant formula, while talc and contraceptive settlement programs face crucial participation cutoffs.
Mass Tort
J&J's $5.5B talc deal depends on a 95% consent threshold — failing to convince 69,000 plaintiffs will send the company back into endless individual jury trials.
BackgroundJohnson & Johnson faced tens of thousands of personal injury lawsuits alleging its cosmetic talc products were contaminated with asbestos and caused ovarian cancer and mesothelioma. The healthcare conglomerate attempted to resolve the liabilities through Chapter 11 bankruptcy filings for a subsidiary, but federal appellate courts repeatedly dismissed the maneuvers.
- The proposed resolution covers approximately 76,000 claimants and features an uncapped structure that could expand toward $7 billion if secondary criteria are met.
- Plaintiffs' attorneys face a rigorous campaign to secure individual client consents before distribution tranches begin processing in early 2027.
- Dissenting plaintiffs' attorneys have argued the payout framework undervalues advanced ovarian cancer cases and are urging clients to opt out.
Mass Tort
Abbott is facing federal jurors in Chicago after a $670M settlement — a plaintiff verdict in this trial would shatter the defense momentum established by Mead Johnson.
BackgroundNecrotizing enterocolitis is a life-threatening intestinal inflammatory disease that predominantly afflicts premature babies fed cow's-milk-derived nutritional fortifiers. Parents filed multidistrict litigation alleging manufacturers marketed infant formulas to neonatal intensive care units without warning of elevated NEC risks compared to human breast milk.
- The trial before Chief Judge Rebecca Pallmeyer in MDL-3026 examines whether Abbott failed to instruct neonatal intensive care units on dietary risks.
- Abbott's $670 million settlement framework resolved roughly 2,000 infant injury claims, but more than 840 active federal lawsuits remain unresolved.
- Mead Johnson parent Reckitt Benckiser recently secured a complete defense verdict in the Inman bellwether trial, creating conflicting jury precedents across the litigation.
Mass Tort
The third Bard PowerPort bellwether is testing manufacturer liability in Arizona — another plaintiff verdict will force Becton Dickinson toward a billion-dollar global settlement.
BackgroundImplanted port catheters are surgically placed beneath the skin to deliver chemotherapy and intravenous medications directly into large bloodstream vessels. Over 4,100 patients filed federal lawsuits alleging Becton Dickinson used excessive barium sulfate in polyurethane catheters, causing the material to crack, fracture, and harbor bacterial colonies.
- The plaintiff in Lattanzio v. Becton Dickinson alleges design defects caused catheter micro-fractures, releasing bacterial biofilm into the bloodstream and inducing septic shock.
- The proceedings follow a $40 million verdict awarded in the second bellwether trial, which held the manufacturer liable for catheter migration and structural failure.
- Judge Campbell ordered both legal teams to track trial testimony under Case Management Order 42 to inform global settlement discussions covering 4,140 active claims.
Mass Tort
Depo-Provera plaintiffs face a November 30 deadline — women with brain tumors must submit medical proof now to participate in Pfizer's nationwide settlement.
BackgroundDepo-Provera is a long-acting injectable progestin contraceptive administered every three months to prevent pregnancy. Medical studies published in European journals demonstrated that prolonged high-dose progestin use significantly elevates the relative risk of developing intracranial meningiomas.
- Case Management Order 14 sets November 30 as the absolute cutoff for claimants to submit neuro-oncology medical records and verified pharmacy proof of use.
- Pfizer's comprehensive settlement framework is projected to resolve roughly 80% of eligible federal MDL claims without proceeding to trial.
- Approved claimant settlement distributions are scheduled to begin processing in early 2027 under an independent claims administration facility.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
